Decreased prolactin levels have been reported in patients receiving pramipexole. One study has shown that pramipexole administration in humans results in a decrease in serum prolactin levels. In this study, pramipexole was administered to healthy adult males at doses of 0.75 to 3.0 mg/day for a period of four weeks (equivalent to 0.15 to 0.6 mg/day for a period of one year). Mean 24–hour serum prolactin levels were significantly lower during pramipexole administration than during baseline. The mean 24–hour serum prolactin levels were also lower during pramipexole administration than during placebo administration. The mean 24–hour serum prolactin levels following administration of 0.3 mg of pramipexole were comparable to the mean 24–hour serum prolactin levels during baseline. The prolactin level should be monitored in patients with Parkinson’s disease who are being treated with pramipexole. If prolactin levels increase above the normal range, consideration should be given to reducing the dose of pramipexole.
Pramipexole
$125.00
Increase in blood pressure has been reported in patients taking pramipexole. In controlled clinical trials in patients with idiopathic Parkinson’s disease, the mean change from baseline in systolic blood pressure was +4.4 mm Hg for the 0.25 mg dose, +4.9 mm Hg for the 0.5 mg dose, and +6.0 mm Hg for the 0.75 mg dose. In the same trials, the mean change from baseline in diastolic blood pressure was +2.0 mm Hg, +2.1 mm Hg and +2.5 mm Hg, respectively. In addition, in controlled clinical trials in patients with restless legs syndrome, the mean change from baseline in systolic blood pressure was +2.2 mm Hg for the 0.25 mg dose and +0.5 mm Hg for the 0.5 mg dose. In the same trials, the mean change from baseline in diastolic blood pressure was +1.3 mm Hg and +0.5 mm Hg, respectively. It is unknown whether these findings are related to pramipexole or other factors. In Parkinson’s disease patients, treatment with pramipexole should be started at a dose of 0.25 mg/day and should be increased gradually until optimal response is achieved. The maximum recommended dose is 1.5 mg/day. In patients with restless legs syndrome, treatment with pramipexole should be started at a dose of 0.5 mg/day. This dose should be increased gradually until optimal response is achieved. The maximum recommended dose is 1.5 mg/day. In both Parkinson’s disease and restless legs syndrome, changes in blood pressure should be monitored at each visit, and the pramipexole dose should be adjusted accordingly.
Reviews
There are no reviews yet.